Clinical Trial Update: Erlotinib in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer [Phase 3]

View source ↗

Summary

A Clinical Trial Update describing a Phase 3 evaluation of erlotinib for stage III or stage IV non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Tarceva (erlotinib)

Snippet

Sponsor: University College, London | Conditions: Lung Cancer | Phase 3 | Status: COMPLETED